3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Glioblastoma
5
Gliosarcoma
2
Brain Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Metatropic dwarfism
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Carboplatin
235
Pemetrexed
214
Paclitaxel
160
Cisplatin
150
pembrolizumab
145
Erlotinib Hydrochloride
141
Docetaxel
133
Gemcitabine
94
Bevacizumab
85
Nivolumab
72
Radiotherapy
62
atezolizumab
40
Radiosurgery
37
Afatinib
37
osimertinib
35
130-nm albumin-bound paclitaxel
35
Cetuximab
34
durvalumab
33
Ipilimumab
32
Gefitinib
31
Albumin-Bound Paclitaxel
29
Vinorelbine
23
Taxes
22
Etoposide
20
Crizotinib
19
Radiation
17
Sorafenib
16
Cyclophosphamide
16
Dexamethasone
15
Magnetic Resonance Spectroscopy
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Non-Small-Cell Lung
×
Cilengitide
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts